| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8223238 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
Sorafenib can be safely combined with radiation and temozolomide in patients with high-grade glioma and with radiation alone in patients with recurrent glioma. The recommended phase II dose of sorafenib is 200 mg twice daily when combined with temozolomide and radiation and 400 mg with radiation alone. To our knowledge, this is the first publication of concurrent sorafenib with radiation monotherapy or combined with radiation and temozolomide.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Robert B. MD, Mitchell MD, Zhi PhD, Maria MD, Erin BA, Michelle BA, Yaacov R. MRCP, Sarah MPhil, Terry PhD, David W. MD, Jon MD, David P. MD, Michael R. MD, PhD, Kevin MD, Adam P. MD, PhD,